[2026 update] What the GIP component of tirzepatide is thought to contribute, and how confident we can be posts 31–60

On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.

A weak preference rather than a position.

Confirming post #45 from a second method, which matters more than confirming it from a second person.

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

Noting that I have skin in this question and have tried to discount for it.

Post #45 describes the usual case. This is about the unusual one.

Answering the GIP component of tirzepatide question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.

Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.

For anyone finding this later: the short answer on GIP component of tirzepatide is that it depends on one thing, and the rest of the thread is people identifying which thing.

Thank you for taking the time. That was more work than a reply usually is.

Taking post #48 at face value and following it one step further.

Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not recommending it.

The disagreement above is smaller than it looks once the terms are fixed.

Post #51 and I disagree about the size of the effect, not about the direction.

On the mechanism question specifically: the honest position is that GIP agonism plausibly contributes and that the trial design cannot separate its contribution from simply achieving greater receptor engagement overall.

That distinction has done more work for me than anything else in this category.

On GIP component of tirzepatide I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

Reporting rather than recommending, on GIP component of tirzepatide. What happened is above. Whether it should have is a different question and not one I am qualified to answer.

Building on post #52 rather than restating it.

The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.

If that is already documented somewhere, ignore me and link it.

Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.

The strength of my opinion here exceeds the strength of my evidence.

What I can speak to on GIP component of tirzepatide is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.

That is consistent with mine, for whatever one more account is worth.

Where the GIP component of tirzepatide discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.

Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They depend entirely on where the threshold was drawn.